Valued at a\u00a0market cap of $10.8 billion, Charles River Laboratories International, Inc. (CRL)\u00a0is a global contract research organization (CRO) headquartered in Wilmington, Massachusetts. It supports the drug discovery and development process for pharmaceutical, biotechnology, medical device, and government clients worldwide.<\/p>\n
It is expected to announce its fiscal\u00a0Q4 earnings\u00a0for 2025 soon. Before this event, analysts expect this\u00a0healthcare company to report a\u00a0profit of $2.33 per share,\u00a0down 12.4% from\u00a0$2.66 per share\u00a0in the year-ago quarter.\u00a0The company has a promising trajectory of consistently beating Wall Street\u2019s bottom-line estimates in each of the last four quarters.<\/p>\n
For fiscal 2025, analysts expect CRL to report a profit of $10.22 per share, down 1% from\u00a0$10.32 per share\u00a0in fiscal 2024. Nonetheless, its EPS is expected to rebound and grow by 4.9% year over year to $10.72 in fiscal 2026.<\/p>\n CRL has\u00a0increased 32.5%\u00a0over the past 52 weeks, outperforming the S&P 500 Index’s ($SPX)\u00a016.9% uptick\u00a0and the Health Care Select Sector SPDR Fund\u2019s (XLV)\u00a010.4% rise\u00a0over the same time period.<\/p>\n Shares of Charles River Laboratories rose about 3% on Dec. 22, after BofA Securities upgraded the stock to \u201cBuy\u201d and the SEC closed its investigation into the company\u2019s primate sourcing practices without taking enforcement action, removing a major overhang for investors.<\/p>\n Wall Street analysts are\u00a0moderately optimistic\u00a0about CRL\u2019s stock, with an overall “Moderate Buy” rating. Among 16 analysts covering the stock, 11 recommend “Strong Buy,” and five suggest “Hold.\u201d While the stock currently trades above the mean price target of $209.57, its Street-high target of $260 implies an upswing potential of 18.3% from the current market prices.<\/p>\n On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on Barchart.com <\/i><\/p>\n<\/p><\/div>\n<\/div>\n<\/div>
<\/div>\n<\/div>